Bipolar Disorder: Current Guidelines & Evidence

1. Diagnosis & Classification (DSM-5-TR)

• Elevated/expansive/irritable mood plus increased goal-directed activity or energy
• ≥3 additional symptoms: grandiosity, decreased sleep need, pressured speech, flight of ideas, distractibility, psychomotor agitation, reckless behavior

2. Acute Mania / Hypomania

First-line treatment

• Stop any antidepressants — this is the first step upon onset of mania (see flowchart below)
• SGAs are more rapidly efficacious than mood stabilizers for acute mania; efficacy across agents is broadly similar in network meta-analyses, with risperidone possibly showing a slight edge
• Adjunctive SGA + mood stabilizer is more effective than monotherapy with either alone

Monotherapy options (approved for acute mania)

• Add short-term benzodiazepine (lorazepam or clonazepam) for agitation in all patients
• If inadequate response after 1–2 weeks: combine antipsychotic + valproate or lithium

3. Bipolar Depression

Guideline-specific recommendations

Drugs with strong evidence for bipolar depression (FDA-licensed or guideline-endorsed)

⚠️ Antidepressants: May precipitate mania/rapid cycling. Use at minimum dose for minimum duration, only when a mood stabilizer is already in place. Not recommended as monotherapy.

Efficacy ranking (2023 network meta-analysis, 101 RCTs, Lancet Psychiatry [PMID 37595997]):

Olanzapine/fluoxetine > Quetiapine > Olanzapine > Lurasidone > Lumateperone > Cariprazine > Lamotrigine

4. Maintenance / Prophylaxis

Evidence hierarchy for maintenance

1. Lithium — gold standard; best evidence for preventing mania and depression; proven anti-suicide effect (Cipriani et al.); lithium + valproate combination is superior to valproate alone (BALANCE trial)
2. Quetiapine — robust evidence for prevention of both poles
3. Valproate — evidence for both poles, but monotherapy inferior to lithium (BALANCE); avoid in women of childbearing potential
4. Lamotrigine — primarily protects against depressive recurrence; 2024 meta-analysis (PMID 38750644): RR 0.84 vs. placebo; comparable to lithium in relapse prevention
5. Aripiprazole — FDA-approved for maintenance; LAI effective (predominantly prevents mania)
6. Olanzapine — effective; metabolic burden limits long-term use
7. Carbamazepine — somewhat less effective than lithium; significant drug interactions

Key principle: Continue the acute-phase regimen that worked. Withdrawing antipsychotics from a Li/valproate combination may worsen relapse risk.

Long-acting injectables (LAIs)

• Aripiprazole LAI (FDA-approved for maintenance): reduces relapses significantly vs. placebo (26.5% vs. 51.1%); predominantly protects against mania
• Risperidone LAI: effective for manic/hypomanic episodes; does not protect against depressive relapse
• Consider LAIs when adherence is a concern

5. Rapid Cycling

• Lithium may be less effective; combination therapy often needed
• Valproate, lamotrigine, olanzapine used
• Identify and correct precipitants: hypothyroidism, antidepressant use, substance misuse, sleep disruption

6. Special Populations

Pregnancy & Postpartum (ACOG CPG No. 5, CANMAT 2024 [PMID 39936923])

• Valproate: contraindicated (teratogenicity, neurodevelopmental effects)
• Lithium: use with caution (Ebstein anomaly risk is lower than historically thought but still monitor; fetal echocardiography recommended)
• Lamotrigine: relatively safer option
• ECT: considered for severe, refractory cases
• Risk of relapse postpartum is very high — do not abruptly discontinue mood stabilizers

Late-onset Bipolar

• New-onset mania in midlife/later life is often secondary to medical conditions (CNS tumors, steroids, thyroid disease, vascular events) — investigate thoroughly before diagnosing idiopathic bipolar disorder

7. Non-Pharmacological Treatments

• Psychotherapy: CBT, family-focused therapy, interpersonal and social rhythm therapy (IPSRT), and psychoeducation are adjunctive standard of care — they support adherence, reduce relapse triggers, and improve psychosocial functioning
• ECT: Effective for refractory mania or depression, catatonia, or when medication is contraindicated (e.g., pregnancy)
• Lifestyle: Regular sleep-wake cycles are critical — phase advance of circadian rhythms can precipitate mania; light exposure management, sleep hygiene, exercise
• rTMS / dTMS: Emerging evidence (systematic review [PMID 38759496]); not yet guideline-endorsed as primary treatment

8. Physical Monitoring (Maudsley 15th ed.)

Key Recent Evidence Updates